Ingibitory dipeptidilpeptidazy-4: novye vozmozhnosti effektivnogo glikemicheskogo kontrolya putem korrektsii narusheniy zhirovogo obmena u patsientov s sakharnym diabetom 2 tipa
- Authors: Gusenbekova D.G1, Ametov A.S1, Butaeva S.G1
-
Affiliations:
- Issue: No 10 (2015)
- Pages: 49-54
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288013
- ID: 288013
Cite item
Open Access
Access granted
Abstract
The article presents the results of the study, which was aimed to the evaluation of the effect of sitagliptin in combination with metformin on parameters of lipid metabolism in patients with type 2 diabetes mellitus. The study included 82 patients (55.3±9.1 years) who have not reached the target glycated hemoglobin levels, with overweight and dyslipidemia. The first group (42 individuals) have received sitagliptin 100 mg/day in combination with metformin 2.0 g/day; before entering the study, patients have received monotherapy with metformin 1.5-2.0 g/day. The second group (40 patients) have received monotherapy with metformin 2.0 g/day; before entering the study, these patients were on diet therapy. Fasting glucose levels, postprandial glucose, HbA1c, body weight, body mass index, waist circumference, waist circumference/hip circumference, lipid profile, insulin, leptin, adiponectin, HOMAIR (insulin resistance index), HOMA-ß (ß-pancreatic cells functional activity index) were assessed at baseline and at 6 months. MRI of visceral fat was performed. Against the background of combined therapy with sitagliptin and metformin, more pronounced important nonglicemic effects in the form of reduced visceral fat depot, increase of adiponectin levels and decrease of leptin levels were observed compared to monotherapy with metformin.
Full Text
References
- IDF Diabetes Atlas Sixth Edition, International Diabetes Federation
- Unger R.H. Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 2001;15:312-21
- Ожирение / Под ред. И.И. Дедова, Г.А. Мельниченко, С.А. Бутрова. М., 2004. 56 с.
- Cohen D.H., LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocrine Related Cancer. BioScientifica. 2012;19(5):27-45.
- Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. 3-е изд., перераб. и доп. М., 2015. Т. 2. 34 с.
- Rosenbaum M., Goldsmith R., Bloomfield D., Magnano A., Weimer L., Heymsfield S., Gallagher D., Mayer L., Murphy E,. Leibel R.L. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. Journal of Clinical Investigation. Am. Soc. Clin. Investigat. 2005;115(12):3579-86.
- Farooqi I.S., O'Rahilly S. Monogenic Obesity in Humans. Annual Review of Medicine. Ann. Rev. 2005;56(1):443-58.
- Zhang X, Zhang G., Zhang H., Karin M., Bai H., Cai D. Hypothalamic IKKß/NF-κΒ and ER Stress Link Over nutrition to Energy Imbalance and Obesity. Cell. 2008;135(1):61-73.
- Kleinridders A., Schenten D., Könner A.C., Belgardt B.F., Mauer J., Okamura T., Wunderlich F.T., Medzhitov R., Brüning J.C. MyD88 Signaling in the CNS Is Required for Development of Fatty Acid-Induced Leptin Resistance and Diet-Induced Obes. Cell Metab. 2009; 10(4):249-59.
- Posey K.A., Clegg D.J., Printz R.L., A., Byun J., Morton G.J., Vivekanandan-Giri A., Pennathur S., Baskin D.G., Heinecke J.W., Woods S.C., Schwartz M.W., Niswender K.D. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. AJP: Endocrinology and Metabolism. Am. Physiol.Soc. 2008;296(5):E1003-E1012.
- Van Genugten R.E., Möller-Goede D.L., van Raalte D.H., Diamant M. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diab. Obes. Metab. 2013;15(7): 593-606.
- Аметов А.С., Камынина Л.Л. Негликемические эффекты ингибиторов дипептидилпепти-дазы-4. Тер.архив. 2013;1:98-102.
Supplementary files
